Management of renal complications in patients with advanced multiple myeloma

被引:2
|
作者
Viertel, A [1 ]
Weidmann, E [1 ]
Ditting, T [1 ]
Geiger, H [1 ]
机构
[1] Univ Frankfurt, Med Clin 4, Div Nephrol, D-6000 Frankfurt, Germany
关键词
chemotherapy; clinical outcome; multiple myeloma; renal impairment; renal replacement therapy;
D O I
10.3109/10428190009059270
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Although the kidney is frequently involved in malignant monoclonal gammopathy, the clinical outcome of the patients varies considerably. We retrospectively assessed the clinical course in seventeen patients with acute and chronic renal failure suffering from multiple myeloma, and analyzed their case history focusing on the therapeutic management, the possible clinical improvement as well as the patients' outcome. Treatment included chemotherapy (n = 17), forced diuresis (n = 3), hemodialysis (n = 11, 7 chronic, 4 intermittent) and plasmapheresis (n = 3). Renal function improved in five patients, and was stabilized compensated in four. Seven patients developed end-stage renal disease, one refused further treatment and was lost for follow up. In addition to renal failure, the most frequent complications included local bone destruction (all), anemia (n = 12, low platelet count (n = 11), and bacterial infections (n = 9), One year survival rate after admission to the nephrology department was 76 percent. Chemotherapy in combination with renal replacement therapy may improve the clinical course even in MM patients with serum creatinine levels above 3.0 mg/dL or end-stage renal disease.
引用
收藏
页码:513 / 519
页数:7
相关论文
共 50 条
  • [41] Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study
    Chanan-Khan, Asher A.
    Kaufman, Jonathan L.
    Mehta, Jayesh
    Richardson, Paul G.
    Miller, Kena C.
    Lonial, Sagar
    Munshi, Nikhil C.
    Schlossman, Robert
    Tariman, Joseph
    Singhal, Seema
    BLOOD, 2007, 109 (06) : 2604 - 2606
  • [42] Management of infectious complications in multiple myeloma patients: Expert panel consensus-based recommendations
    Girmenia, Corrado
    Cavo, Michele
    Offidani, Massimo
    Scaglione, Francesco
    Corso, Alessandro
    Di Raimondo, Francesco
    Musto, Pellegrino
    Petrucci, Maria Teresa
    Barosi, Giovanni
    BLOOD REVIEWS, 2019, 34 : 84 - 94
  • [43] Clinical utility of biochemical markers of bone metabolism for improving the management of patients with advanced multiple myeloma
    Lipton, Allan
    Cook, Richard J.
    Coleman, Robert E.
    Smith, Matthew R.
    Major, Pierre
    Terpos, Evangelos
    Berenson, James R.
    CLINICAL LYMPHOMA & MYELOMA, 2007, 7 (05): : 346 - 353
  • [44] Bone complications in multiple myeloma
    Berenson, James R.
    Rajdev, Lakshmi
    Broder, Michael
    CANCER BIOLOGY & THERAPY, 2006, 5 (09) : 1082 - 1085
  • [45] Management of cardiovascular risk in patients with multiple myeloma
    Chris Plummer
    Christoph Driessen
    Zsolt Szabo
    María-Victoria Mateos
    Blood Cancer Journal, 9
  • [46] SYMPTOM ASSESSMENT AND MANAGEMENT IN MULTIPLE MYELOMA PATIENTS
    Noonan, Kimberly
    ONCOLOGY NURSING FORUM, 2019, 46 (02)
  • [47] The Outcome of Management of Multiple Myeloma in Sudanese Patients
    Idriss, Mutasim
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S575 - S575
  • [48] COMPLICATIONS OF MULTIPLE-MYELOMA
    HAMMER, AS
    COUTO, CG
    JOURNAL OF THE AMERICAN ANIMAL HOSPITAL ASSOCIATION, 1994, 30 (01) : 9 - 14
  • [49] Pain Management in Patients with Multiple Myeloma: An Update
    Coluzzi, Flaminia
    Rolke, Roman
    Mercadante, Sebastiano
    CANCERS, 2019, 11 (12)
  • [50] Management of cardiovascular risk in patients with multiple myeloma
    Plummer, Chris
    Driessen, Christoph
    Szabo, Zsolt
    Mateos, Maria-Victoria
    BLOOD CANCER JOURNAL, 2019, 9 (3)